Core Insights - IMUNON, Inc. announced positive results from a Phase 1 clinical trial of its investigational DNA plasmid vaccine, IMNN-101, which demonstrated better durability of protection compared to mRNA vaccines after a single dose targeting the SARS-CoV-2 Omicron XBB1.5 variant [3][4] - The company is seeking strategic partnerships to advance its PlaCCine technology platform and fund its core pipeline with non-dilutive capital [1][4] Company Overview - IMUNON is a clinical-stage biotechnology company focused on developing non-viral DNA-mediated immunotherapies and next-generation vaccines [1][8] - The company's lead clinical program, IMNN-001, is a DNA-based immunotherapy for advanced ovarian cancer, which has completed multiple clinical trials [9] Clinical Trial Details - The Phase 1 trial enrolled 24 participants and evaluated three escalating doses of IMNN-101, with a focus on safety, tolerability, and immunogenicity [6] - Results indicated a median increase of up to 3-fold in serum neutralizing antibody titers at six months, with no serious adverse effects reported [3][6] Technology Advantages - The PlaCCine technology platform offers several competitive advantages, including better durability of protection, temperature stability, and ease of manufacturing compared to current mRNA vaccines [4][5] - IMNN-101 utilizes a proprietary DNA plasmid that regulates the expression of key pathogen antigens, providing flexibility in manufacturing and delivery [5]
IMUNON Announces PlaCCine® DNA Vaccine Technology Abstract Selected for Oral Presentation at 10th International Conference on Vaccines Research & Development™